An In Vitro And In Vivo Evaluation Of Novel Indigenously-Designed Controlled Release Flurbiprofen Gel System For Management Of Periodontal Diseases.

Periodontal diseases are mainly the immune-inflammatory diseases caused by the microbial accumulations on the tooth surfaces. These microorganisms release number of chemical mediators which stimulates the series of host inflammatory response. Various Chemotherapeutic agents have been tried to modulate host response. Flurbiprofen is a non-steroidal antiinflammatory drug widely researched as host modulating agent for periodontal diseases. A controlled release drug delivery system was designed for the effective delivery of flurbiprofen to the periodontal tissues with minimum side effects. The present study was undertaken to evaluate the in vitro and in vivo release of the drug from the novel indigenously prepared delivery system. The results of the study showed the sustained release of the drug from the system in the effective concentration for the period of 14 days.